Daniel Barnett, MD
Neurology · Albuquerque, NMNPI 1639699259
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Livanova USA, Inc. accounts for 71.6% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $163, 2.9 times the $56 reported in 2023. That places this record below the midpoint for neurology clinicians in NM, where the typical reported total is $623.
Across 24 payments — averaging $12.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$217
- Ceribell, Inc.$41
- SK Life Science, Inc.$27
- Neuropace, Inc.$17
Across 154 payments — averaging $368.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neuropace, Inc.$57K
What the payments were for
- Food & beverage$303100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 20 | $217 |
| Ceribell, Inc. | 2 | $41 |
| SK Life Science, Inc. | 1 | $27 |
| Neuropace, Inc. | 1 | $17 |
How this compares
$303 in reported general payments places this provider in the 35th percentile of 91 neurology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BriviactBrivaracetam | 38 | $104,289 |
| NayzilamMidazolam | 11 | $10,068 |
| Lacosamide | 51 | $8,682 |
| Levetiracetam | 121 | $4,732 |
| Clobazam | 34 | $2,357 |
| Oxcarbazepine | 27 | $2,305 |
| Carbamazepine ErCarbamazepine | 32 | $1,966 |
| Lamotrigine | 81 | $1,926 |
| Divalproex Sodium ErDivalproex Sodium | 34 | $1,696 |
| Divalproex Sodium | 32 | $1,385 |
| Topiramate | 19 | $536 |
| Phenytoin Sodium Extended | 17 | $441 |
| Zonisamide | 18 | $242 |
| Pregabalin | 14 | $214 |
| Clonazepam | 14 | $49 |
Paid to pharmacies, not to this prescriber.
Other neurology in Albuquerque
- Elaine EdmondsAlbuquerque$610K
- Kader AbdelerahmanAlbuquerque$607K
- Timothy OwnbeyAlbuquerque$90K
- Gerson Suarez CedenoAlbuquerque$44K
- Corey FordAlbuquerque$27K
- Diksha MohantyAlbuquerque$20K
- Douglas BarrettAlbuquerque$19K
- Vanessa Licona SanjuanAlbuquerque$16K
- Daniel ShibuyaAlbuquerque$13K
- Alfred van BaakAlbuquerque$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.